Safety and efficacy of Immune checkpoint Inhibitors (ICIs) plus chemotherapy versus chemotherapy alone for small cell lung cancer (SCLC): A systematic review and meta-analysis of randomized controlled trials

被引：0
|
作者：
Mu, Xiaohong [1 ]
Wang, Yunfang [2 ]
Fan, Zhengye [3 ]
Yi, Kang [2 ]
机构：
[1] Huanxian Peoples Hosp, Dept Cardiovasc Med, Qingyang 745700, Peoples R China
[2] Gansu Prov Hosp, Lanzhou 730000, Peoples R China
[3] First Hosp Longnan City, Longnan 742500, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2025年 / 48卷 / 01期
关键词：
ETOPOSIDE;
D O I：
10.1016/j.asjsur.2024.07.155
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：805 / 806
页数：2
相关论文
共 50 条
  • [31] The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
    Yang, Y.
    Luo, H.
    Zheng, X. L.
    Ge, H.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (06): : 1117 - 1127
  • [32] PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials
    Li, Chenxi
    Hao, Meiqi
    Fang, Zige
    Ding, Jiatong
    Duan, Sijia
    Yi, Fengming
    Wei, Yiping
    Zhang, Wenxiong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (03) : 203 - 217
  • [33] Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Mamede, Isadora
    Escalante-Romero, Lorena
    Celso, Davi S. Goncalves
    Reis, Pedro C. Abrahao
    Dacoregio, Maria Inez
    Alves, Ana Caroline
    Stecca, Carlos
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [34] PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials
    Chenxi Li
    Meiqi Hao
    Zige Fang
    Jiatong Ding
    Sijia Duan
    Fengming Yi
    Yiping Wei
    Wenxiong Zhang
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 203 - 217
  • [35] Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials
    Xiao, Yong-Ying
    Zhan, Ping
    Yuan, Dong-Mei
    Liu, Hong-Bing
    Lv, Tang-Feng
    Shi, Yi
    Song, Yong
    CLINICAL ONCOLOGY, 2013, 25 (01) : E7 - E15
  • [36] The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
    Y. Yang
    H. Luo
    X. L. Zheng
    H. Ge
    Clinical and Translational Oncology, 2021, 23 : 1117 - 1127
  • [37] Efficacy and Safety of Ipilimumab plus Chemotherapy for Advanced Lung Cancer: A Systematic Review and Meta-Analysis
    Zhang, Hongman
    Shen, Jie
    Yi, Lilan
    Zhang, Wei
    Luo, Peng
    Zhang, Jian
    JOURNAL OF CANCER, 2018, 9 (23): : 4556 - 4567
  • [38] Immunotherapy plus chemotherapy versus chemotherapy alone in metastatic non small-cell lung cancer: A systematic review with meta-analysis.
    Sasse, Andre Deeke
    Ferreira, Fernanda Proa
    de Oliveira Scherr, Adolfo Jose
    Cunha, David Pinheiro
    Antunes Vasconcelos, Vivian Castro
    Botelho Ramalho, Susana Oliveira
    Conceicao, Vinicius Correa
    Moura Lima do Carmo, Rafael Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
    Yang, Fang
    Wang, Yucai
    Tang, Lin
    Mansfield, Aaron Scott
    Adjei, Alex A. A.
    Leventakos, Konstantinos
    Duma, Narjust
    Wei, Jia
    Wang, Lifeng
    Liu, Baorui
    Molina, Julian R. R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [40] Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
    Li, Yunhai
    Xing, Lei
    Li, Fan
    Liu, Hong
    Gan, Lu
    Yang, Dejuan
    Wang, Mengxue
    Yin, Xuedong
    Li, Hongyuan
    Ren, Guosheng
    FRONTIERS IN ONCOLOGY, 2021, 11
12345